Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yuanjun Yang
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years. Patients with a confirmed diagnosis of chronic kidney disease (CKD). Currently receiving stable, standard-dose SGLT2i therapy at screening. Proteinuria ≥0.15 g/24 h (or urine protein-to-creatinine ratio \[UPCR\] ≥440 mg/g or urine albumin-to-creatinine ratio \[UACR\] ≥300 mg/g) at screening.
Estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m² calculated by the CKD-EPI creatinine equation at screening.
Willing and able to provide written informed consent.
You may not be if
Discontinuation of SGLT2i during the follow-up period. History of symptomatic hypotension (systolic blood pressure\<90 mmHg) without antihypertensive medication, or current hypotensive episode at screening.
Unstable renal function (e.g., acute kidney injury or rapidly progressive glomerulonephritis with a \>50% decline in eGFR within 3 months prior to screening).
Use of corticosteroids or having an indication for corticosteroid therapy within the past 6 months.
Receipt of immunosuppressive therapy or having an indication for immunosuppressive therapy within the past 6 months.
History of intolerance to SGLT2 inhibitors. History of ketoacidosis within the past 5 years.
Clareo Health | Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors
